- 91-7088989654
- harkapharmaceuticals@gmail.com
Triple Power for Comprehensive Glycemic Control
Key Benefits
- Targets multiple pathways in type 2 diabetes
- Controls fasting and postprandial blood glucose
- Reduces insulin resistance and glucose absorption
- Convenient once/twice daily dosing
- Minimizes risk of hypoglycemia and weight gain
Indications:
- Type 2 Diabetes Mellitus
- Inadequate glycemic control on monotherapy
- Patients requiring combination therapy for better sugar control
Composition (Each Uncoated Tablet Contains):
Voglibose – 0.2 mg (An alpha-glucosidase inhibitor that delays glucose absorption from the intestine)
Glimepiride – 2 mg (A sulfonylurea that stimulates insulin release from pancreatic $\beta$-cells)
Metformin Hydrochloride – 500 mg (A biguanide that improves insulin sensitivity and reduces hepatic glucose production)
Voglika GM2 A comprehensive, triple-combination anti-diabetic oral medication engineered to achieve multi-pathway glycemic control in individuals with type 2 diabetes.Specially formulated for managing Type 2 Diabetes Mellitus, particularly for patients who exhibit inadequate glycemic control on single-drug monotherapy.